EPHX2 and type 1 diabetes mellitus: This study showed that both sEH knockout and t-AUCB treatment prevented hyperglycaemia in type I diabetes through enhanced islet glucose-stimulated insulin release by the alternate pathway and decreased islet cell apoptosis [33].